[Ipilimumab and metastatic lung cancer: Can we change the natural history of the disease?]. / Ipilimumab et cancer bronchique métastatique : peut-on changer l'histoire naturelle de la maladie ?
Rev Mal Respir
; 32(9): 949-52, 2015 Nov.
Article
em Fr
| MEDLINE
| ID: mdl-25725978
INTRODUCTION: Ipilimumab (anti CTLA-4 antibody) aims to activate antitumor immunity. This treatment is being evaluated in non-small cell lung cancer. CASE REPORT: We report a case of a stage IV adenocarcinoma patient randomized in 2008 in the phase II trial CA 184-104 evaluating the combination of ipilimumab to chemotherapy with carboplatin and paclitaxel. After an initial partial response to chemotherapy, the patient achieved a complete response with ipilimumab as maintenance therapy. However, it was complicated by grade 3 gastro-intestinal toxicity leading to stop the ipilimumab. However, this complete response persists after 6 years. CONCLUSIONS: Our case illustrates the contribution of immunotherapy at least in some patients. The mechanisms of action, relationship between efficacy and toxicity and predictors of efficacy remain to be defined.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Contexto em Saúde:
3_ND
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
/
Prognostic_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
Fr
Revista:
Rev Mal Respir
Ano de publicação:
2015
Tipo de documento:
Article